October 1, 2021

Press release

Member of the board of directors Shomit Ghose has stopped selling FluoGuide shares, after have sold 4500 shares in the period 28 to 30 September 2021

Copenhagen, Denmark, 1 October 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) today announces that Shomit Ghose (board member) has sold... [Read more]

September 27, 2021

Press release

Member of the board of directors Shomit Ghose sells 3000 shares

Copenhagen, Denmark, 27 September 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) today announces that Shomit Ghose (board member) has sold... [Read more]

September 27, 2021

Press release

Member of the board of directors Shomit Ghose sells 3000 shares

Copenhagen, Denmark, 24 September 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) today announces that Shomit Ghose (board member) has sold... [Read more]

September 22, 2021

Press release

Member of the board of directors Shomit Ghose sells 2000 shares

Copenhagen, Denmark, 22 September 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) today announces that Shomit Ghose (board member) has sold... [Read more]

September 20, 2021

Press release

Member of the board of directors Shomit Ghose sells 2000 shares

Copenhagen, Denmark, 20 September 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) today announces that Shomit Ghose (board member) has sold... [Read more]

September 14, 2021

Press release

Executive management members and members of the Board of Directors buys shares and board member Shomit Ghose sells shares

Copenhagen, Denmark, 14 September 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) today announces that Morten Albrechtsen (CEO), Andreas Kjær (CSO),... [Read more]

September 14, 2021

Press release

FluoGuide proceeds to seventh dose level (36 mg) with FG001 in the ongoing clinical phase I/II trial following continued improvement of tumor illumination with increasing doses

Copenhagen, Denmark, 14 September 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that FG001 was well tolerated,... [Read more]

August 26, 2021

Press release

FluoGuide announces regulatory approval from Swedish Authorities (MPA and Ethics committee) to commence Phase II clinical trial with FG001 in guiding surgery of high grade glioma in Sweden

Copenhagen, Denmark, 26 August 2021 – FluoGuide A/S (“FluoGuide” or “the Company”) is pleased to announce that the company has received... [Read more]

August 25, 2021

Press release

FluoGuide A/S publishes interim report for the period January – June 2021

Copenhagen, Denmark, 25 August 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its results for the period 1 January... [Read more]